glp-1 agonists and retained gastric contents at endoscopy Impact of Glucagon-like Peptide-1 Receptor (GLP-1 RAs) on Increased Residual Content in Patients With Without Concurrent Colonoscopy: A Retrospective Case–Control Study Glucagon-like peptide-1 receptor agonists before
Description
Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.
FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) are commercially available
Introduction The global obesity market is entering a new phase
A new short-term CMS demonstration changes that for 18 months.
Medical-grade dual receptor agonist with expert physician monitoring and personalized weight loss protocols.
Eat less, move more is not a long-term weight management solution
